Orandi At 5 years of follow-up, significantly fewer GLP-1 drug users (7.5%) than nonusers (12.2%) experienced death-censored graft loss, for a 49% lower risk for graft loss with GLP-1 drug use when adjusted for insulin use (adjusted subhazard ratio [aSHR] = 0.51
Understanding this side effect, recognizing those at risk, and implementing prevention and management strategies are crucial for patient safety
Some mild GI changes may persist longer, but severe nausea lasting beyond month two is uncommon
Enhances Endurance As discussed in its introduction carnitine plays an important role in the energy production process
Take the Precision Peptide Genetic Test to understand the GLP-1, appetite-regulation, and energy-balance variants that shape every weight-management decision before any protocol
Promotes a more even-looking skin tone by working from within